Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective?

Hsieh CR, Sloan FA.

Value Health. 2008 Mar-Apr;11(2):334-44. doi: 10.1111/j.1524-4733.2007.00235.x.

2.
4.
5.

The evolution of Taiwan's National Health Insurance drug reimbursement scheme.

Hsu JC, Lu CY.

Daru. 2015 Feb 10;23:15. doi: 10.1186/s40199-014-0080-7. Review.

6.

Propaganda or the cost of innovation? Challenging the high price of new drugs.

Ghinea N, Lipworth W, Kerridge I.

BMJ. 2016 Mar 11;352:i1284. doi: 10.1136/bmj.i1284. Review. No abstract available.

PMID:
26968991
7.

Impact of separating drug prescribing and dispensing on provider behaviour: Taiwan's experience.

Chou YJ, Yip WC, Lee CH, Huang N, Sun YP, Chang HJ.

Health Policy Plan. 2003 Sep;18(3):316-29.

PMID:
12917273
8.

Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003.

Lee YC, Yang MC, Huang YT, Liu CH, Chen SB.

Pharmacoeconomics. 2006;24(9):891-902.

PMID:
16942123
9.

The drug budget silo mentality: the French case.

Le Pen C.

Value Health. 2003 Jul-Aug;6 Suppl 1:S10-9.

PMID:
12846922
10.
11.

New drugs and the growth of health expenditure: evidence from diabetic patients in Taiwan.

Liu YM, Hsieh CR.

Health Econ. 2012 May;21(5):496-513. doi: 10.1002/hec.1724. Epub 2011 Mar 10.

PMID:
21394819
12.
13.

Drugs cheaper than threepenny: the market of extremely low-priced drugs within the National Health Insurance in Taiwan.

Wang BR, Chou CL, Hsu CC, Chou YC, Chen TJ, Chou LF.

ScientificWorldJournal. 2014 Feb 25;2014:234941. doi: 10.1155/2014/234941. eCollection 2014.

14.

Endogenous technological change in medicine and its impact on healthcare costs: evidence from the pharmaceutical market in Taiwan.

Hsieh CR, Liu YM, Chang CL.

Eur J Health Econ. 2013 Apr;14(2):287-95. doi: 10.1007/s10198-011-0370-7. Epub 2011 Dec 27.

PMID:
22200844
15.

[Assessment of the pharmaceutical expenditure in Hungary].

Inotai A, Merész G, Kaló Z.

Acta Pharm Hung. 2010;80(4):162-72. Hungarian.

PMID:
21404477
16.

The economic aspects of drug use.

Haaijer-Ruskamp FM, Dukes MN.

WHO Reg Publ Eur Ser. 1993;45:125-45. No abstract available.

PMID:
8442842
17.

The impact of a national prescription drug formulary on prices, market share, and spending: lessons for Medicare?

Huskamp HA, Epstein AM, Blumenthal D.

Health Aff (Millwood). 2003 May-Jun;22(3):149-58.

18.

Spending on medicines in Israel in an international context.

Sax P.

Isr Med Assoc J. 2005 May;7(5):286-91.

19.

Pricing of prescription drugs and its impact on physicians' choice behavior.

Miao-Sheng C, Yu-Ti S.

Health Care Manag Sci. 2008 Sep;11(3):288-95.

PMID:
18826006
20.

The impact of reference-pricing systems in Europe: a literature review and case studies.

Dylst P, Vulto A, Simoens S.

Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):729-37. doi: 10.1586/erp.11.70. Review.

PMID:
22098289

Supplemental Content

Support Center